Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
70 hedge funds and large institutions have $509M invested in Blueprint Medicines in 2015 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 10 closing their positions.
46% more call options, than puts
Call options by funds: $102K | Put options by funds: $70K
38% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 21
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
0% more funds holding
Funds holding: 70 → 70 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
17% less capital invested
Capital invested by funds: $610M → $509M (-$101M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.94M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$4.57M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
+$3.81M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.6M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$4.71M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.78M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.97M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$2.55M |
| 5 |
Millennium Management
New York
|
-$1.25M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BG
76
BlackRock Group
London,
United Kingdom
| – | -$178K | -6,724 | Closed |
|
|
GGHC
77
Gilder Gagnon Howe & Co
New York
| – | -$125K | -4,710 | Closed |
|
|
SO
78
STRS Ohio
Columbus,
Ohio
| – | -$83K | -3,000 | Closed |
|
79
US Bancorp
Minneapolis,
Minnesota
| – | -$29K | -1,096 | Closed |
|
80
Invesco
Atlanta,
Georgia
| – | -$5K | -177 | Closed |
|
BPMC Hedge Fund Activity: Q3 2015 in Review
70 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2015, worth a combined $509M — down 17% from $610M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new BPMC positions and 10 closed out — a net gain of 1 holder — while 29 added to existing stakes and 21 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $4.94M. The largest seller was JP Morgan Chase, cutting an estimated $4.71M.
- 70 institutional investors held Blueprint Medicines (BPMC) as of Q3 2015, unchanged from Q2 2015.
- Funds reported $509M of Blueprint Medicines stock for Q3 2015, down 17% quarter-over-quarter.
- 11 funds opened new Blueprint Medicines positions in Q3 2015 and 10 closed out, a net change of +1 holder.
- The largest Blueprint Medicines buyer in Q3 2015 was Deutsche Bank, an estimated $4.94M added.
- The largest Blueprint Medicines seller in Q3 2015 was JP Morgan Chase, an estimated $4.71M sold.
Based on aggregated 13F filings for Q3 2015.